News
Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97
6 May 24
News, Upgrades, Price Target, Analyst Ratings
Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168
6 May 24
News, Price Target, Analyst Ratings
Citigroup Maintains Sell on Blueprint Medicines, Raises Price Target to $76
3 May 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Blueprint Medicines, Raises Price Target to $135
3 May 24
News, Price Target, Analyst Ratings
JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125
3 May 24
News, Price Target, Analyst Ratings
Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $75
3 May 24
News, Price Target, Analyst Ratings
Piper Sandler Maintains Neutral on Blueprint Medicines, Raises Price Target to $104
3 May 24
News, Price Target, Analyst Ratings
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $130
3 May 24
News, Price Target, Analyst Ratings
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
2 May 24
News, Intraday Update, Markets, Movers
Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
2 May 24
News, Price Target, Reiteration, Analyst Ratings
Blueprint Medicines Corp Expects 2024 Global AYVAKIT Net Product Revenues of $390M-$410M (Prior $360M-$390M)
2 May 24
News, Guidance
Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate
2 May 24
Earnings, Earnings Beats, News
12 Health Care Stocks Moving In Wednesday's After-Market Session
1 May 24
Movers
Stifel Maintains Buy on Blueprint Medicines, Raises Price Target to $130
26 Apr 24
News, Price Target, Analyst Ratings
Wedbush Reiterates Outperform on Blueprint Medicines, Maintains $110 Price Target
26 Apr 24
News, Price Target, Reiteration, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $125 Price Target
26 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
26 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Decoding 6 Analyst Evaluations For Blueprint Medicines
10 Apr 24
Analyst Ratings
JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
26 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 May 24
Press Releases
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
2 May 24
Earnings, Press Releases
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
11 Apr 24
Press Releases
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Press Releases
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 Mar 24
News, Contracts, Press Releases
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
23 Feb 24
Press Releases
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
15 Feb 24
Earnings, Press Releases